JP2016523910A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016523910A5 JP2016523910A5 JP2016524170A JP2016524170A JP2016523910A5 JP 2016523910 A5 JP2016523910 A5 JP 2016523910A5 JP 2016524170 A JP2016524170 A JP 2016524170A JP 2016524170 A JP2016524170 A JP 2016524170A JP 2016523910 A5 JP2016523910 A5 JP 2016523910A5
- Authority
- JP
- Japan
- Prior art keywords
- binding protein
- antigen binding
- seq
- antigen
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000025171 antigen binding proteins Human genes 0.000 claims description 160
- 108091000831 antigen binding proteins Proteins 0.000 claims description 160
- 150000001413 amino acids Chemical class 0.000 claims description 24
- 238000013262 cAMP assay Methods 0.000 claims description 22
- 238000003556 assay Methods 0.000 claims description 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
- 230000003247 decreasing effect Effects 0.000 claims description 12
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 claims description 10
- 210000004027 cell Anatomy 0.000 claims description 10
- 108010000239 Aequorin Proteins 0.000 claims description 8
- 108091006027 G proteins Proteins 0.000 claims description 8
- 102000030782 GTP binding Human genes 0.000 claims description 8
- 108091000058 GTP-Binding Proteins 0.000 claims description 8
- 101000710899 Homo sapiens Cannabinoid receptor 1 Proteins 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 8
- 230000011664 signaling Effects 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 4
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
- 230000002503 metabolic effect Effects 0.000 claims description 4
- 102000011690 Adiponectin Human genes 0.000 claims description 2
- 108010076365 Adiponectin Proteins 0.000 claims description 2
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 102000004877 Insulin Human genes 0.000 claims description 2
- 108090001061 Insulin Proteins 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 230000008485 antagonism Effects 0.000 claims description 2
- 230000036772 blood pressure Effects 0.000 claims description 2
- 238000004113 cell culture Methods 0.000 claims description 2
- 235000012000 cholesterol Nutrition 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 238000005265 energy consumption Methods 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 229940125396 insulin Drugs 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 2
- 239000013598 vector Substances 0.000 claims description 2
- 230000004580 weight loss Effects 0.000 claims description 2
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361839458P | 2013-06-26 | 2013-06-26 | |
| US61/839,458 | 2013-06-26 | ||
| PCT/US2014/044164 WO2014210205A1 (en) | 2013-06-26 | 2014-06-25 | Cb1 receptor antigen-binding proteins and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018159121A Division JP2018201516A (ja) | 2013-06-26 | 2018-08-28 | Ｃｂ１受容体抗原結合タンパク質及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016523910A JP2016523910A (ja) | 2016-08-12 |
| JP2016523910A5 true JP2016523910A5 (enExample) | 2017-06-29 |
| JP6562912B2 JP6562912B2 (ja) | 2019-08-21 |
Family
ID=51177217
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016524170A Active JP6562912B2 (ja) | 2013-06-26 | 2014-06-25 | Ｃｂ１受容体抗原結合タンパク質及びその使用 |
| JP2018159121A Withdrawn JP2018201516A (ja) | 2013-06-26 | 2018-08-28 | Ｃｂ１受容体抗原結合タンパク質及びその使用 |
| JP2020152622A Active JP7018104B2 (ja) | 2013-06-26 | 2020-09-11 | Ｃｂ１受容体抗原結合タンパク質及びその使用 |
| JP2021201683A Withdrawn JP2022037087A (ja) | 2013-06-26 | 2021-12-13 | Ｃｂ１受容体抗原結合タンパク質及びその使用 |
| JP2023145208A Withdrawn JP2023171760A (ja) | 2013-06-26 | 2023-09-07 | Ｃｂ１受容体抗原結合タンパク質及びその使用 |
| JP2025103642A Pending JP2025163008A (ja) | 2013-06-26 | 2025-06-19 | Ｃｂ１受容体抗原結合タンパク質及びその使用 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018159121A Withdrawn JP2018201516A (ja) | 2013-06-26 | 2018-08-28 | Ｃｂ１受容体抗原結合タンパク質及びその使用 |
| JP2020152622A Active JP7018104B2 (ja) | 2013-06-26 | 2020-09-11 | Ｃｂ１受容体抗原結合タンパク質及びその使用 |
| JP2021201683A Withdrawn JP2022037087A (ja) | 2013-06-26 | 2021-12-13 | Ｃｂ１受容体抗原結合タンパク質及びその使用 |
| JP2023145208A Withdrawn JP2023171760A (ja) | 2013-06-26 | 2023-09-07 | Ｃｂ１受容体抗原結合タンパク質及びその使用 |
| JP2025103642A Pending JP2025163008A (ja) | 2013-06-26 | 2025-06-19 | Ｃｂ１受容体抗原結合タンパク質及びその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10227406B2 (enExample) |
| EP (1) | EP3013860B1 (enExample) |
| JP (6) | JP6562912B2 (enExample) |
| AU (1) | AU2014302410B2 (enExample) |
| CA (1) | CA2915386A1 (enExample) |
| WO (1) | WO2014210205A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6598844B2 (ja) | 2014-03-27 | 2019-10-30 | バード・ロック・バイオ・インコーポレイテッド | ヒトカンナビノイド１（ｃｂ１）受容体に結合する抗体 |
| JP2019502651A (ja) * | 2015-09-30 | 2019-01-31 | バード・ロック・バイオ・インコーポレイテッドＢｉｒｄ Ｒｏｃｋ Ｂｉｏ， Ｉｎｃ． | ヒトカンナビノイド１（ｃｂ１）受容体に結合する抗体 |
| CA3066733A1 (en) | 2017-06-09 | 2018-12-13 | President And Fellows Of Harvard College | Method to identify compounds useful to treat dysregulated lipogenesis, diabetes, and related disorders |
| JP2020537506A (ja) | 2017-10-04 | 2020-12-24 | アムジエン・インコーポレーテツド | トランスサイレチン免疫グロブリン融合物 |
| CN112218684A (zh) | 2018-04-30 | 2021-01-12 | 武田药品工业株式会社 | 大麻素受体1型(cb1)结合蛋白及其用途 |
| JP7430624B2 (ja) | 2020-11-27 | 2024-02-13 | 株式会社ブリヂストン | タイヤ組立体 |
| KR102707476B1 (ko) | 2021-01-28 | 2024-09-20 | 주식회사 파미노젠 | 피라졸-카르복스아미드 유도체 화합물 및 이의 용도 |
| JPWO2023234406A1 (enExample) | 2022-06-03 | 2023-12-07 | ||
| WO2024022478A1 (zh) * | 2022-07-28 | 2024-02-01 | 长春金赛药业有限责任公司 | 结合大麻素受体cb1的抗体及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005023232A2 (en) * | 2003-09-04 | 2005-03-17 | Affibody Ab | Therapeutic, screening and diagnostic methods based on the effect of cb1 receptor modulation on lymphoproliferative disorders. |
| US7655685B2 (en) | 2007-11-02 | 2010-02-02 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
| GB2456183A (en) | 2008-01-04 | 2009-07-08 | Gw Pharma Ltd | Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament |
| EP2382204B1 (en) * | 2008-12-23 | 2018-07-11 | Merck Sharp & Dohme Corp. | Pyrimidine derivatives as gpcr modulators for use in the treatment of obesity and diabetes |
| US20130059890A1 (en) | 2009-12-18 | 2013-03-07 | Sydney West Area Health Service | Antiviral agents |
-
2014
- 2014-06-25 AU AU2014302410A patent/AU2014302410B2/en active Active
- 2014-06-25 CA CA2915386A patent/CA2915386A1/en active Pending
- 2014-06-25 WO PCT/US2014/044164 patent/WO2014210205A1/en not_active Ceased
- 2014-06-25 US US14/899,551 patent/US10227406B2/en active Active
- 2014-06-25 EP EP14739018.1A patent/EP3013860B1/en active Active
- 2014-06-25 JP JP2016524170A patent/JP6562912B2/ja active Active
-
2018
- 2018-08-28 JP JP2018159121A patent/JP2018201516A/ja not_active Withdrawn
-
2020
- 2020-09-11 JP JP2020152622A patent/JP7018104B2/ja active Active
-
2021
- 2021-12-13 JP JP2021201683A patent/JP2022037087A/ja not_active Withdrawn
-
2023
- 2023-09-07 JP JP2023145208A patent/JP2023171760A/ja not_active Withdrawn
-
2025
- 2025-06-19 JP JP2025103642A patent/JP2025163008A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016523910A5 (enExample) | ||
| MX392435B (es) | Anticuerpos estables y solubles que inhiben el vegf. | |
| BR112015022978A2 (pt) | agente de ligação biespecífico, seu método de produção composição farmacêutica, proteína de fusão, uso, sequência de ácido nucleico, vetor, célula hospedeira, método de matar células tumorais e de inibir o crescimento tumoral | |
| JP2014518883A5 (enExample) | ||
| TN2014000536A1 (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| BR112012018914A2 (pt) | "anticorpo humanizado, proteína de ligação de antígeno, molécula de ácido nucleico, vetor de expressão, célula hospedeira recombinante, proteína de ligação de anticorpo ou de antígeno, métodos para a produção de uma proteína de ligação de antígeno e para tratar um sujeito afetado por uma doença autoimune ou inflamatória, e, composição farmacêutica." | |
| FI3736291T3 (fi) | Anti-fcrh5-vasta-aineita | |
| BR112014030797A2 (pt) | epítopo de peptídeo isolado, proteína recombinante, molécula de ácido nucléico isolada, vetor, célula hospedeira, método para preparar o epítopo de peptídeo ou mutante do mesmo, vacina de proteína, uso do epítopo de peptídeo ou mutante do mesmo, vacina de gene, uso da molécula de ácido nucléico, composição farmacêutica, anticorpo monoclonal e um fragmento de ligação ao antígeno do mesmo, linha de célula de hibridoma, kit, método para detecção da presença ou nível da proteína hbsag em uma amostra e uso do anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo | |
| JP2015501814A5 (enExample) | ||
| JP2015525230A5 (enExample) | ||
| JP2012520679A5 (enExample) | ||
| JP2015214563A5 (enExample) | ||
| AR073978A1 (es) | Anticuerpos humanos de alta afinidad para el receptor il-4-humano | |
| EP4342529A3 (en) | Anti-c5 antibodies and methods of use | |
| MX351682B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| PH12017501114B1 (en) | Anti-c5 antibodies and methods of use | |
| AR086360A1 (es) | Polipeptidos anticuerpos que antagonizan cd40 | |
| BR112012024710A8 (pt) | moléculas que se ligam ao antígeno, seus processos de produção, bem como composição farmacêutica que as compreendem | |
| MX394165B (es) | Anticuerpos anti-receptor ccr7 humanizados. | |
| BR112015019603A2 (pt) | Moléculas de ácido nucleico isoladas, molécula de polipeptídeo isolada, molécula isolada de car, domínio de ligação anti-egfrviii, vetor, célula e uso de uma quantidade eficaz da mesma e métodos para produção de uma célula e para a produção de uma população de células modificadas por rna | |
| BRPI0915928B8 (pt) | anticorpo isolado ou proteína funcional e composição farmacêutica compreendendo os mesmos | |
| AR093803A1 (es) | Composiciones y metodos de anticuerpos de marcaje de epo | |
| MY187848A (en) | Anti-c5 antibodies and methods of use | |
| PE20130207A1 (es) | Anticuerpos antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones | |
| JP2008530138A5 (enExample) |